What’s Propelling AxoGen, Inc. (AXGN) to Reach All-Time High?

March 16, 2018 - By Migdalia James

The stock of AxoGen, Inc. (NASDAQ:AXGN) reached all time high today, Mar, 16 and still has $38.21 target or 3.00 % above today’s $37.10 share price. This indicates more upside for the $1.28 billion company. This technical setup was reported by Barchart.com. If the $38.21 PT is reached, the company will be worth $38.40M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

It closed at $37.1 lastly. It is up 181.49% since March 16, 2017 and is uptrending. It has outperformed by 164.79% the S&P500.

Analysts await AxoGen, Inc. (NASDAQ:AXGN) to report earnings on May, 3. They expect $-0.11 EPS, 0.00 % or $0.00 from last year’s $-0.11 per share. After $-0.07 actual EPS reported by AxoGen, Inc. for the previous quarter, Wall Street now forecasts 57.14 % negative EPS growth.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 8 analysts covering AxoGen (NASDAQ:AXGN), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 21 analyst reports since August 11, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, February 28 report. Wedbush maintained it with “Outperform” rating and $12 target in Monday, November 7 report. Wedbush maintained AxoGen, Inc. (NASDAQ:AXGN) on Friday, August 28 with “Outperform” rating. The firm has “Buy” rating given on Tuesday, November 22 by Lake Street. Cantor Fitzgerald maintained the shares of AXGN in report on Monday, January 8 with “Buy” rating. The company was upgraded on Tuesday, August 11 by Zacks. Roth Capital maintained the stock with “Buy” rating in Monday, September 11 report. The rating was maintained by Leerink Swann with “Outperform” on Thursday, November 2. JMP Securities maintained AxoGen, Inc. (NASDAQ:AXGN) on Thursday, March 1 with “Market Outperform” rating. On Friday, March 2 the stock rating was maintained by Lake Street with “Buy”.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $1.28 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.